We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+7.39%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$7.43B
AUM Growth
+$757M
(+11%)
Cap. Flow
+$285M
Cap. Flow
% of AUM
3.83%
Top 10 Holdings %
Top 10 Hldgs %
21.69%
Holding
281
New
28
Increased
104
Reduced
67
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$124M |
| 2 |
Medtronic
MDT
|
+$67.1M |
| 3 |
Becton Dickinson
BDX
|
+$51.8M |
| 4 |
RTX Corp
RTX
|
+$51.1M |
| 5 |
Humana
HUM
|
+$44.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$82.1M |
| 2 |
Baxter International
BAX
|
+$49.3M |
| 3 |
Incyte
INCY
|
+$42.4M |
| 4 |
Stryker
SYK
|
+$34.6M |
| 5 |
Pediatrix Medical
MD
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.39% |
| 2 | Healthcare | 23.32% |
| 3 | Technology | 19.99% |
| 4 | Communication Services | 10.16% |
| 5 | Industrials | 7.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AWH
101
DELISTED
Allied World Assurance Co Hld Lt
AWH
| $26.5M | 0.36% |
501,700
| – | – |
|
102
Criteo
CRTO
$1.03B
| $26.5M | 0.36% |
539,401
+116,777
| +28% | +$5.93M |
|
103
Fidelity National Information Services
FIS
$21.5B
| $25.4M | 0.34% |
297,270
| – | – |
|
104
Carnival Corporation Ltd
CCL
$36.1B
| $25.3M | 0.34% |
386,074
| – | – |
|
|
MDSO
105
DELISTED
Medidata Solutions, Inc.
MDSO
| $25.2M | 0.34% |
321,996
-52,696
| -14% | -$3.67M |
|
106
Lam Research
LRCX
$382B
| $24.9M | 0.34% |
1,759,940
-47,000
| -3% | -$689K |
|
107
Freeport-McMoran
FCX
$90B
| $23.8M | 0.32% |
1,985,501
+274,410
| +16% | +$3.33M |
|
|
TLND
108
DELISTED
Talend S.A. American Depositary Shares
TLND
| $23.6M | 0.32% |
679,860
-113,520
| -14% | -$3.7M |
|
109
RingCentral
RNG
$4.05B
| $23.6M | 0.32% |
645,873
-253,555
| -28% | -$8.38M |
|
|
MIME
110
DELISTED
Mimecast Limited
MIME
| $23.4M | 0.31% |
+872,353
| New | +$21.9M |
|
111
8x8 Inc
EGHT
$247M
| $23.2M | 0.31% |
1,598,630
+205,300
| +15% | +$2.91M |
|
|
EVBG
112
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $22.8M | 0.31% |
936,976
+118,635
| +14% | +$2.83M |
|
113
Pegasystems
PEGA
$4.41B
| $22.7M | 0.31% |
779,972
-438,756
| -36% | -$11.6M |
|
114
BioMarin Pharmaceuticals
BMRN
$11.5B
| $22.2M | 0.3% |
244,211
-238,089
| -49% | -$21.7M |
|
|
AXDX
115
DELISTED
Accelerate Diagnostics
AXDX
| $22M | 0.3% |
+80,497
| New | +$21.8M |
|
|
QTNT
116
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $21.9M | 0.3% |
+74,500
| New | +$21M |
|
|
QVCGA
117
DELISTED
QVC Group Inc Series A
QVCGA
| $21.6M | 0.29% |
18,152
-549
| -3% | -$608K |
|
|
PRA
118
DELISTED
ProAssurance
PRA
| $21.3M | 0.29% |
351,100
+2,800
| +0.8% | +$168K |
|
119
MACOM Technology Solutions
MTSI
$20.4B
| $21.1M | 0.28% |
+377,700
| New | +$20.4M |
|
120
FIVE9
FIVN
$1.77B
| $20.4M | 0.27% |
949,272
-619,151
| -39% | -$12.7M |
|
|
ALXN
121
DELISTED
Alexion Pharmaceuticals
ALXN
| $20M | 0.27% |
164,712
-273,522
| -62% | -$31.8M |
|
|
122
Merck
MRK
$324B
| $19.5M | 0.26% |
318,871
-1,348,289
| -81% | -$82.1M |
|
|
XYZ
123
Block Inc
XYZ
$45.9B
| $19.3M | 0.26% |
824,199
+554,820
| +206% | +$11.5M |
|
124
Lumentum
LITE
$59.4B
| $19.3M | 0.26% |
+338,795
| New | +$18.2M |
|
|
PTLA
125
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $19M | 0.26% |
+337,500
| New | +$13.5M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2017 Portfolio in Review
As of Q2 2017, Polar Capital held 281 positions worth $7.43B, up 11% from $6.67B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital deployed $285M of net new capital in Q2 2017, opening 28 new positions and adding to 104 existing holdings. Its largest new stake was RTX Corp: 681,946 shares worth $52.4M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Merck, an estimated $82.1M trimmed.
- Polar Capital's largest Q2 2017 buy was RTX Corp: 681,946 shares worth $52.4M.
- Polar Capital added most to Johnson & Johnson in Q2 2017, an estimated $124M increase.
- Polar Capital's biggest Q2 2017 reduction was Merck, cutting an estimated $82.1M.
- Polar Capital fully exited Baxter International in Q2 2017, selling an estimated $49.3M.
- Polar Capital's ten largest holdings make up 22% of its $7.43B portfolio in Q2 2017.
- Polar Capital opened 28 new positions and closed 44 in Q2 2017.
- Polar Capital's portfolio value rose 11% quarter-over-quarter to $7.43B.
Based on Polar Capital's 13F filing for Q2 2017, filed 14 Aug 2017.